Response-durability phenotypes and clinical benefit with erdafitinib: a THOR trial post hoc analysis.

Nakagawa R, Hori T, Kamijima T, Kadomoto S, Makino T, Naito R, Iwamoto H, Yaegashi H, Shigehara K, Nohara T, Izumi K, Mizokami A

Open source

DOI: 10.1111/bju.70533
Published: 2026 Nov 9
Container: BJU international
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/bju.70533,
  title = {Response-durability phenotypes and clinical benefit with erdafitinib: a THOR trial post hoc analysis.},
  author = {Nakagawa R and Hori T and Kamijima T and Kadomoto S and Makino T and Naito R and Iwamoto H and Yaegashi H and Shigehara K and Nohara T and Izumi K and Mizokami A},
  year = {2026},
  journal = {BJU international},
  doi = {10.1111/bju.70533},
  url = {https://doi.org/10.1111/bju.70533}
}

RIS

TY  - JOUR
TI  - Response-durability phenotypes and clinical benefit with erdafitinib: a THOR trial post hoc analysis.
AU  - Nakagawa R
AU  - Hori T
AU  - Kamijima T
AU  - Kadomoto S
AU  - Makino T
AU  - Naito R
AU  - Iwamoto H
AU  - Yaegashi H
AU  - Shigehara K
AU  - Nohara T
AU  - Izumi K
AU  - Mizokami A
PY  - 2026
JO  - BJU international
DO  - 10.1111/bju.70533
UR  - https://doi.org/10.1111/bju.70533
ER  -

APA

R, N., T, H., T, K., S, K., T, M., R, N., H, I., H, Y., K, S., T, N., K, I., & A, M. (2026). Response-durability phenotypes and clinical benefit with erdafitinib: a THOR trial post hoc analysis.. BJU international. https://doi.org/10.1111/bju.70533

Source records

pubmed · retrieved 2026-11-10T06:11:42.852Z